drugset / Trial / NCT00399438

A Study of BMS-562086 in Patients With Irritable Bowel Syndrome

NCT00399438

Phase 2 Completed 39 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blind

Summary

The primary purpose of this study is to evaluate the effects of BMS-562086 on small bowel and colonic transits in female subjects with diarrhea-predominant irritable bowel syndrome (D-IBS)

Timeline

Start
2006-12
Primary completion
2007-10
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pexacerfont Small molecule 25 mg Oral
Subject Pexacerfont Small molecule 100 mg Oral